Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 2Urethral Neoplasms 2Ureteral Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 2Triple Negative Breast Neoplasms 2Carcinoma, Transitional Cell 2Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 6Magnetic Resonance Spectroscopy 4Gemcitabine 3Biopsy 3eribulin 2cabozantinib 2atezolizumab 2pembrolizumab 1erdafitinib 1enfortumab vedotin 1carotuximab 1avelumab 1Watchful Waiting 1Platinum 1Observation 1Nivolumab 1Lenalidomide 1Ipilimumab 1Interleukin-7 1Immunoglobulin G 1Disulfides 1Cystoscopy 1Contrast Media 1Cisplatin 1Carboplatin 1CTLA-4 Antigen 1Bortezomib 1Bevacizumab 1Arsenic Trioxide 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Ureteral Neoplasms × eribulin × Clear all
NCT03237780 2026-05-13

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
72 enrolled
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT02178241 2019-12-16

Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
26 enrolled 9 charts

Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡